The Swiss stock market, represented by the Swiss Market Index (SMI), has reached a new all-time high. The record-breaking performance was driven by significant gains among major blue-chip companies, including pharmaceutical giants Novartis and Roche, as well as food and beverage leader Nestlé, reflecting positive investor sentiment in the Swiss economy.
The Australian mRNA therapeutics sector is poised for substantial expansion, with market projections estimating a valuation of USD 1.78 billion by 2035. This growth is underpinned by strategic government initiatives and increased private sector investment aimed at establishing Australia as a global hub for mRNA research, development, and manufacturing.
Rhythm Pharmaceuticals has officially launched IMCIVREE (setmelanotide) in Japan. It is the first therapy approved in the country for the treatment of obesity caused by acquired hypothalamic injury, offering a new medical option for patients suffering from this rare and complex condition.
The Cuban government has introduced new regulatory frameworks for private pharmacies as part of ongoing economic reforms. These measures aim to address chronic medication shortages and improve the distribution of essential pharmaceutical products across the country amid a challenging economic climate.
Amid persistent economic challenges and pharmaceutical shortages in Cuba, community-led initiatives and local projects in Havana are stepping up to provide essential medicines to citizens, offering a vital lifeline for those struggling to access standard healthcare supplies.
The Supreme Court of India has ordered the Union government to constitute an expert committee to address unethical marketing practices in the pharmaceutical industry. The directive aims to ensure transparency and accountability, following concerns regarding the influence of pharmaceutical companies on medical professionals and patient welfare.
Italy's Garante per la protezione dei dati personali has fined IQVIA Solutions Italy 7 million euros. The penalty follows an investigation revealing that the company failed to properly anonymize health data belonging to approximately one million patients, violating European data protection regulations.
Saudi authorities have launched a nationwide campaign to curb the illegal online sale of peptides. The Saudi Food and Drug Authority (SFDA) is targeting unauthorized platforms and distributors to protect public health, warning that these substances often lack safety approvals and pose significant risks to consumers.
Paramount has secured a settlement with California and other U.S. states regarding its proposed $81 billion merger with Warner Bros. Discovery. This agreement resolves regulatory concerns and marks a significant step forward in the consolidation process for the media giants, aiming to reshape the competitive landscape of the entertainment industry.
In a significant healthcare policy development, the Trump administration announced that all 50 U.S. states have agreed to participate in a new Medicaid drug pricing model. Designed to curb rising prescription costs, the initiative aims to increase transparency and leverage collective purchasing power to secure better pricing for state Medicaid programs across the country.
Associate Health Minister David Seymour has announced a Pharmac proposal to widen funded access to the gout medication febuxostat. The move aims to improve treatment options for thousands of New Zealanders suffering from the condition, with the proposal currently open for public consultation to gather feedback from patients, clinicians, and the wider health sector.
Walmart has finalized a $3.1 billion settlement with the U.S. Department of Justice and various state governments. The agreement resolves long-standing allegations that the retail giant failed to properly oversee opioid prescriptions, contributing to the national opioid crisis. The settlement includes requirements for enhanced compliance and monitoring protocols.
Shionogi & Co. and SUSMED Co. have mutually agreed to terminate their commercialization agreement for a digital therapeutic application designed to treat insomnia in Japan. The decision ends a strategic partnership focused on bringing digital health solutions to the Japanese market, with both companies citing a strategic realignment regarding the product's future development.
South African pharmaceutical and medical device manufacturers are scaling operations to bolster regional healthcare supply chains. Leveraging the African Continental Free Trade Area (AfCFTA), these companies aim to reduce reliance on imports and enhance medicine security across the continent through increased intra-African trade and manufacturing capacity.
A daily oral medication, Rybelsus, containing the active ingredient semaglutide, is now available in UK pharmacies via private prescription. While primarily indicated for type 2 diabetes, the drug is being prescribed off-label for weight management, offering an alternative to injectable treatments for eligible patients seeking to manage their health.
A US federal judge has ruled against the Department of Defense, blocking the Pentagon from designating WuXi AppTec as a 'Chinese military company.' The court found that the government failed to provide sufficient evidence to support the classification, marking a significant legal setback for the Pentagon's efforts to restrict the Chinese pharmaceutical giant's operations in the United States.
Novo Nordisk South Africa has entered a strategic partnership with pharmaceutical company Acino to introduce a more affordable version of its semaglutide diabetes treatment. This initiative aims to improve access to essential care for patients living with type 2 diabetes across South Africa, addressing the growing need for cost-effective therapeutic options in the region.
Leading Australian medical and science organizations have expressed significant concern regarding proposed changes to the Research and Development Tax Incentive. Industry experts warn that the adjustments could stifle innovation and negatively impact the country's life sciences sector, potentially hindering critical medical research and development projects.
Swiss pharmaceutical giant Novartis has officially opened a new state-of-the-art facility in Ljubljana, Slovenia. The site is dedicated to the sterile filling and packaging of complex biologics and xRNA medicines, marking a significant expansion of the company's manufacturing capabilities in Europe to support the production of innovative therapies.
Swiss pharmaceutical company Roche has announced promising clinical trial results for its investigational drug, divarasib. The study evaluated the efficacy of the treatment in patients with non-small cell lung cancer harboring specific KRAS G12C mutations, marking a potential advancement in targeted therapy options for this patient population.
